ATE275970T1 - Impfstoffzusammensetzungen - Google Patents
ImpfstoffzusammensetzungenInfo
- Publication number
- ATE275970T1 ATE275970T1 AT94928455T AT94928455T ATE275970T1 AT E275970 T1 ATE275970 T1 AT E275970T1 AT 94928455 T AT94928455 T AT 94928455T AT 94928455 T AT94928455 T AT 94928455T AT E275970 T1 ATE275970 T1 AT E275970T1
- Authority
- AT
- Austria
- Prior art keywords
- double mutant
- antigen
- substituted
- manufacture
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 3
- 230000003000 nontoxic effect Effects 0.000 abstract 3
- 108010081690 Pertussis Toxin Proteins 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 241000588832 Bordetella pertussis Species 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939320454A GB9320454D0 (en) | 1993-10-05 | 1993-10-05 | Vaccine compositions |
GB939324743A GB9324743D0 (en) | 1993-12-02 | 1993-12-02 | Adjuvant compositions |
PCT/GB1994/002152 WO1995009649A1 (en) | 1993-10-05 | 1994-10-04 | Vaccine compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE275970T1 true ATE275970T1 (de) | 2004-10-15 |
Family
ID=26303633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94928455T ATE275970T1 (de) | 1993-10-05 | 1994-10-04 | Impfstoffzusammensetzungen |
Country Status (7)
Country | Link |
---|---|
US (2) | US7169399B2 (de) |
EP (1) | EP0725653B2 (de) |
AT (1) | ATE275970T1 (de) |
AU (1) | AU7788194A (de) |
DE (1) | DE69434000T3 (de) |
DK (1) | DK0725653T3 (de) |
WO (1) | WO1995009649A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
ATE275970T1 (de) | 1993-10-05 | 2004-10-15 | Celltech Pharmaceuticals Ltd | Impfstoffzusammensetzungen |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) * | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
KR20050044523A (ko) * | 2001-11-19 | 2005-05-12 | 벡톤 디킨슨 앤드 컴퍼니 | 입자 형태의 약제학적 조성물 |
EP1790358A1 (de) * | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Proteinkonstrukte designed zum Targeting und Lyse von Zellen |
NZ602958A (en) | 2010-03-30 | 2014-07-25 | Pfenex Inc | High level expression of recombinant toxin proteins |
IN2014CN04700A (de) * | 2011-12-21 | 2015-09-18 | Bionet Asia Co Ltd | |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
WO2016011155A1 (en) * | 2014-07-15 | 2016-01-21 | Kapre Subhash V | Genetically detoxified pertussis that maintains intrinsic adjuvant activity |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8727489D0 (en) * | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
JPH03500606A (ja) | 1988-05-05 | 1991-02-14 | アプライド マイクロバイオロジー,インコーポレイテッド | プロテアーゼ欠損グラム陽性菌類及び組換え体産生用宿主有機体としての用途 |
AP8900132A0 (en) * | 1988-07-22 | 1991-01-14 | Smithkline Biolog | Bordetella pertussis vaccine |
DK0396964T3 (da) * | 1989-04-28 | 1995-10-30 | Sclavo Spa | Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner |
US5601826A (en) * | 1989-06-30 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
DK0425082T3 (da) | 1989-09-04 | 1995-07-03 | Evans Medical Ltd | Vacciner |
JPH03135923A (ja) * | 1989-10-20 | 1991-06-10 | Chemo Sero Therapeut Res Inst | 百日咳毒素bオリゴマーの構成サブユニットを含有する経鼻接種ワクチン |
IT1248735B (it) | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
EP0484621A3 (en) | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
CA2083553A1 (en) | 1991-11-25 | 1993-05-26 | Kuniharu Seki | Immunogen composition |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
ATE275970T1 (de) | 1993-10-05 | 2004-10-15 | Celltech Pharmaceuticals Ltd | Impfstoffzusammensetzungen |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
DK1117435T3 (da) | 1998-09-30 | 2008-03-17 | Wyeth Corp | Muteret cholera-holotoxin som adjuvans |
-
1994
- 1994-10-04 AT AT94928455T patent/ATE275970T1/de not_active IP Right Cessation
- 1994-10-04 DE DE69434000T patent/DE69434000T3/de not_active Expired - Fee Related
- 1994-10-04 AU AU77881/94A patent/AU7788194A/en not_active Abandoned
- 1994-10-04 DK DK94928455T patent/DK0725653T3/da active
- 1994-10-04 EP EP94928455A patent/EP0725653B2/de not_active Expired - Lifetime
- 1994-10-04 WO PCT/GB1994/002152 patent/WO1995009649A1/en active IP Right Grant
-
2001
- 2001-02-02 US US09/775,909 patent/US7169399B2/en not_active Expired - Fee Related
-
2007
- 2007-01-09 US US11/651,346 patent/US20100255033A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69434000T3 (de) | 2008-11-06 |
DE69434000T2 (de) | 2005-01-27 |
US20100255033A1 (en) | 2010-10-07 |
DE69434000D1 (de) | 2004-10-21 |
DK0725653T3 (da) | 2004-10-11 |
AU7788194A (en) | 1995-05-01 |
US20010018056A1 (en) | 2001-08-30 |
EP0725653B2 (de) | 2008-04-02 |
EP0725653A1 (de) | 1996-08-14 |
WO1995009649A1 (en) | 1995-04-13 |
EP0725653B1 (de) | 2004-09-15 |
US7169399B2 (en) | 2007-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ291262A (en) | E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants | |
ATE275970T1 (de) | Impfstoffzusammensetzungen | |
UA40596C2 (uk) | Композиція вакцини та спосіб її одержання | |
GB9419979D0 (en) | Vaccine compositions | |
NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
IS3753A7 (is) | Endurbætt aðferð og samsetning bóluefnis | |
HK1121382A1 (en) | Adjuvant compositions for enhancing immune responses to polynucleotide- based vaccines | |
GB9209118D0 (en) | Vaccine compositions | |
HUP9801223A2 (hu) | Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel | |
DE69317435T2 (de) | Entzündungshemmende tolerogene und inmonoinhibitorische eigenschaften von karbohyhydrate bindenden peptiden | |
FR2693655B1 (fr) | Vaccin antirabique avirulent. | |
GB9500788D0 (en) | Vaccine compositions | |
HK1025220A1 (en) | Novel saponin compositions and uses thereof | |
EA200300557A1 (ru) | Комбинированные композиции адъювантов | |
DE69128095D1 (de) | Azelluläre impfstoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |